Abstract
Objective: Cases of thrombosis have been reported after administration of SARS-CoV-2 vaccines, with controversial results relating to Oxford-AstraZeneca’s ChAdOx1-S. Despite such cases being rare, they still raised concerns for their involvement in coagulopathies. Anti-cardiolipin (aCL) IgG antibodies have been linked to venous and arterial thrombosis. The aim was to evaluate the concentration of aCL IgG antibodies in vaccinated and COVID-19 positive individuals using indirect ELISA and commercial sourced calibrators.
Results: The concentration of aCL IgG antibodies was measured in the serum of COVID-19 positive (n = 37), ChAdOx1-S vaccinated (n = 37) and BioNTech Pfizer BNT162b2 vaccinated (n = 42) individuals. Samples from COVID-19 negative, unvaccinated individuals (n = 41) served as controls. The highest percentage of positivity was in the COVID-19 positive group (18.9%). Concerning vaccination, BNT162b2 had the highest percentage of positivity (11.9%) (p = 0.0037). Additionally, aCL concentrations were evaluated at different time points in both vaccinated groups (before, 3 weeks after and 3 months after the second dose). A significant difference in the levels of aCL IgG antibodies over time (p = 0.0391) was observed only in ChAdOx1-S individuals. Our study concluded that levels of aCL, after vaccination with either of the vaccines or following SARS-CoV-2 infection, were not clinically pathogenic for the risk of thrombosis.
Keywords: BNT162b2; COVID-19; ChAdOx1-S; Coagulopathies; Thrombosis.
【저자키워드】 COVID-19, BNT162b2, Coagulopathies, thrombosis., ChAdOx1-S, 【초록키워드】 vaccination, thrombosis, SARS-COV-2 infection, risk, SARS-CoV-2 vaccines, ELISA, Pfizer, serum, IgG antibody, group, administration, Concentration, Oxford-AstraZeneca, significant difference, second dose, individual, pathogenic, positive, controls, venous, was measured, highest, Sample, evaluate, reported, clinically, evaluated, raised, individuals, the vaccine, different time point, COVID-19 negative, positive individual, 【제목키워드】 vaccination, antibody, SARS CoV, induce,